1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. MMP
  4. MMP-19 Isoform

MMP-19

MMP-19

Matrix metalloproteinase-19 (MMP-19) is a zinc-dependent extracellular matrix protease that participates in tissue remodeling through the degradation of multiple matrix components, including basement membrane-associated substrates, aggrecan, cartilage oligomeric matrix protein, fibronectin, nidogen-1, laminin, and collagen type IV[1][2][3]. Mechanistically, MMP-19 belongs to the matrix metalloproteinase family that regulates extracellular matrix turnover and influences cellular interactions with the surrounding microenvironment during development and tissue homeostasis[4][5]. Its potent activity toward basement membrane components distinguishes MMP-19 as an enzyme capable of modifying structural barriers that control cell migration and tissue organization[2][3]. In experimental systems, MMP-19-mediated processing of nidogen-1 inhibits capillary-like formation, linking extracellular matrix remodeling to angiogenesis-related biological processes. Disease-associated studies further indicate that MMP-19 expression is altered in cancer contexts, and reduced expression has been reported in nasopharyngeal carcinoma, supporting investigation of its potential role in tumor suppression and tumor microenvironment regulation[3]. Compared with related matrix metalloproteinases, MMP-19 displays a distinct substrate spectrum that includes both basement membrane proteins and cartilage-associated extracellular matrix molecules, highlighting functional specialization within the MMP family[2][3]. For experimental applications, broad-spectrum metalloproteinase inhibitors such as batimastat have been used to profile active MMPs, providing a framework for investigating MMP-19 activity in extracellular matrix remodeling and disease models[6].

MMP-19 Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-180115
    Antibacterial agent 315
    Inhibitor
    LP07 is an antibacterial agent targeting Pseudomonas aeruginosa with MIC values for both wild-type and efflux pump-deficient P. aeruginosa PA14 of both 8 μg/mL. LP07 exerts its antibacterial effect by directly disrupting the structural integrity of the bacterial cell membrane. LP07 moderately inhibits MMP-17 and MMP-19, but has no significant inhibitory effect on other MMP subtypes. LP07 does not inhibit the activity of LpxC enzyme. LP07 can be used for research on Pseudomonas aeruginosa infections.